Trillium Therapeutics on Wednesday is announcing an expanded slate of clinical trials meant to advance the development of two cancer drugs that work by blocking a “don’t eat me” signal used by tumors to evade the immune system.
But updated results from earlier studies, also presented Wednesday, show higher doses of the Trillium drugs did not result in improved tumor-response rates — a potential disappointment in a crowded field of similar medicines.
About the Author Reprints
